ASCO Gastrointestinal Cancer Symposium

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.

Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.

The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.

“It does appear like MET expression could be one of the mechanisms wherein you could differentiate between responders and non-responders,” Kanwal P.S. Raghav, MBBS, MD, stated.

Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.

Data from 2025 ASCO GI support the potential role that combinations such as nivolumab/ipilimumab may play a part in managing different types of GI cancers.

Atezolizumab and bevacizumab yielded a median OS of 14.0 months vs 14.6 months with tremelimumab followed by durvalumab, a retrospective cohort study found.

A phase 2 trial found T-DM1 to be a tolerable treatment option for patients with HER2-positive biliary tract adenocarcinoma.

Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.

The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.

At a longer follow-up, adagrasib with cetuximab maintained meaningful efficacy and elicited an ORR of 34%, results from the phase 1/2 KRYSTAL-1 showed.

Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.

Patients with esophageal cancer who received palliative care consultations during end-of-life treatment experienced a decreased financial burden compared with patients who did not.

The ALASCCA trial found that the risk of disease recurrence was reduced by 51% for patients with PIK3CA-mutated colorectal cancer who took aspirin for 3 years.

A phase 2 study evaluated the efficacy of balstilimab and botensilimab in patients with MSS metastatic mCRC without liver metastases.

The BREAKWATER trial found that encorafenib and cetuximab with mFOLFOX6 chemotherapy generated an ORR of 60.9% in BRAF V600E–mutated metastatic colorectal cancer.

Post-operative ctDNA testing led to a change in adjuvant management in 1 of 6 patients with stage II/III colorectal cancer treated in the BESPOKE trial.

Updated results support nivolumab/ipilimumab as a standard of care in patients with MSI-H or dMMR metastatic colorectal cancer.

The results of a real-world study support palliative care integration in patients with advanced early-onset colorectal cancer.

No differences in oncologic outcomes occurred between mandatory TME or selective WW strategy in rectal cancer responders to neoadjuvant therapy.

Synchronous metastatic status does not appear to affect survival among patients with resected BRAF V600E-mutated metastatic colorectal cancer.

A pCR rate of 44% was observed when neoadjuvant pembrolizumab was given to patients with dMMR colon cancer.

Post hoc analysis of the phase 3 NAPOLI 3 trial assessed how dose reductions in liposomal irinotecan/oxaliplatin affect OS in NALIRIFOX-treated PDAC.

The NeoCaCRT trial found that SCRT followed by cadonilimab and mFOLFOX6 elicited a pCR of 37.0%, meeting its primary end point for patients with locally advanced rectal cancer.

Cohort 5 of the ongoing phase 1/2 GOBLET study evaluated the safety of pelareorep in combination with modified FOLFIRINOX with or without atezolizumab in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.

A 3-cohort retrospective analysis compared patients who met eligibility for the NAPOLI 3 trial with all-comers treated with FOLFIRINOX for PDAC.

Findings highlight the challenge of evolving logistics for testing and related decision-making in the treatment of those with gastric or GEJ cancers.

Subgroup analysis of the CALGB/SWOG 80702 trial investigated the impact of ctDNA status on DFS in stage III resected colon cancer patients treated with celecoxib or placebo.

Results from the ACCELERATE trial did not improve relapse-free survival when chemoradiation was added to chemotherapy for patients with resected gallbladder cancer.